220 related articles for article (PubMed ID: 20189109)
1. Affinity reagents that target a specific inactive form of protein kinases.
Ranjitkar P; Brock AM; Maly DJ
Chem Biol; 2010 Feb; 17(2):195-206. PubMed ID: 20189109
[TBL] [Abstract][Full Text] [Related]
2. Affinity purification of protein kinases that adopt a specific inactive conformation.
Ranjitkar P; Maly DJ
Methods Mol Biol; 2012; 928():143-51. PubMed ID: 22956139
[TBL] [Abstract][Full Text] [Related]
3. Predicting inactive conformations of protein kinases using active structures: conformational selection of type-II inhibitors.
Xu M; Yu L; Wan B; Yu L; Huang Q
PLoS One; 2011; 6(7):e22644. PubMed ID: 21818358
[TBL] [Abstract][Full Text] [Related]
4. Structure of mitogen-activated protein kinase kinase 1 in the DFG-out conformation.
Nakae S; Kitamura M; Fujiwara D; Sawa M; Shirai T; Fujii I; Tada T
Acta Crystallogr F Struct Biol Commun; 2021 Dec; 77(Pt 12):459-464. PubMed ID: 34866601
[TBL] [Abstract][Full Text] [Related]
5. Sequence determinants of a specific inactive protein kinase conformation.
Hari SB; Merritt EA; Maly DJ
Chem Biol; 2013 Jun; 20(6):806-15. PubMed ID: 23790491
[TBL] [Abstract][Full Text] [Related]
6. Structural elucidation of the DFG-Asp in and DFG-Asp out states of TAM kinases and insight into the selectivity of their inhibitors.
Messoussi A; Peyronnet L; Feneyrolles C; Chevé G; Bougrin K; Yasri A
Molecules; 2014 Oct; 19(10):16223-39. PubMed ID: 25310149
[TBL] [Abstract][Full Text] [Related]
7. Conformational analysis of the DFG-out kinase motif and biochemical profiling of structurally validated type II inhibitors.
Vijayan RS; He P; Modi V; Duong-Ly KC; Ma H; Peterson JR; Dunbrack RL; Levy RM
J Med Chem; 2015 Jan; 58(1):466-79. PubMed ID: 25478866
[TBL] [Abstract][Full Text] [Related]
8. Exploration of structural requirements for the inhibition of VEGFR-2 tyrosine kinase: Binding site analysis of type II, 'DFG-out' inhibitors.
Modi SJ; Kulkarni VM
J Biomol Struct Dyn; 2022 Aug; 40(12):5712-5727. PubMed ID: 33459187
[TBL] [Abstract][Full Text] [Related]
9. The ABC of protein kinase conformations.
Möbitz H
Biochim Biophys Acta; 2015 Oct; 1854(10 Pt B):1555-66. PubMed ID: 25839999
[TBL] [Abstract][Full Text] [Related]
10. Redefining the Protein Kinase Conformational Space with Machine Learning.
Ung PM; Rahman R; Schlessinger A
Cell Chem Biol; 2018 Jul; 25(7):916-924.e2. PubMed ID: 29861272
[TBL] [Abstract][Full Text] [Related]
11. DFGmodel: predicting protein kinase structures in inactive states for structure-based discovery of type-II inhibitors.
Ung PM; Schlessinger A
ACS Chem Biol; 2015 Jan; 10(1):269-78. PubMed ID: 25420233
[TBL] [Abstract][Full Text] [Related]
12. Lead Discovery of Type II BRAF V600E Inhibitors Targeting the Structurally Validated DFG-Out Conformation Based upon Selected Fragments.
Zhang Q; Zhang X; You Q
Molecules; 2016 Jul; 21(7):. PubMed ID: 27438814
[TBL] [Abstract][Full Text] [Related]
13. Fluorescence labels in kinases: a high-throughput kinase binding assay for the identification of DFG-out binding ligands.
Simard JR; Rauh D
Methods Mol Biol; 2012; 800():95-117. PubMed ID: 21964785
[TBL] [Abstract][Full Text] [Related]
14. Exploration of type II binding mode: A privileged approach for kinase inhibitor focused drug discovery?
Zhao Z; Wu H; Wang L; Liu Y; Knapp S; Liu Q; Gray NS
ACS Chem Biol; 2014 Jun; 9(6):1230-41. PubMed ID: 24730530
[TBL] [Abstract][Full Text] [Related]
15. Conformation-Selective Analogues of Dasatinib Reveal Insight into Kinase Inhibitor Binding and Selectivity.
Kwarcinski FE; Brandvold KR; Phadke S; Beleh OM; Johnson TK; Meagher JL; Seeliger MA; Stuckey JA; Soellner MB
ACS Chem Biol; 2016 May; 11(5):1296-304. PubMed ID: 26895387
[TBL] [Abstract][Full Text] [Related]
16. Prediction of Protein Kinase-Ligand Interactions through 2.5D Kinochemometrics.
Bosc N; Wroblowski B; Meyer C; Bonnet P
J Chem Inf Model; 2017 Jan; 57(1):93-101. PubMed ID: 27983837
[TBL] [Abstract][Full Text] [Related]
17. Defining a new nomenclature for the structures of active and inactive kinases.
Modi V; Dunbrack RL
Proc Natl Acad Sci U S A; 2019 Apr; 116(14):6818-6827. PubMed ID: 30867294
[TBL] [Abstract][Full Text] [Related]
18. Identification of type I and type II inhibitors of c-Yes kinase using in silico and experimental techniques.
Ramakrishnan C; Mary Thangakani A; Velmurugan D; Anantha Krishnan D; Sekijima M; Akiyama Y; Gromiha MM
J Biomol Struct Dyn; 2018 May; 36(6):1566-1576. PubMed ID: 28589758
[TBL] [Abstract][Full Text] [Related]
19. Molecular dynamics simulations show that conformational selection governs the binding preferences of imatinib for several tyrosine kinases.
Aleksandrov A; Simonson T
J Biol Chem; 2010 Apr; 285(18):13807-15. PubMed ID: 20200154
[TBL] [Abstract][Full Text] [Related]
20. Molecular dynamics simulation and free energy calculation studies of kinase inhibitors binding to active and inactive conformations of VEGFR-2.
Wu X; Wan S; Wang G; Jin H; Li Z; Tian Y; Zhu Z; Zhang J
J Mol Graph Model; 2015 Mar; 56():103-12. PubMed ID: 25594497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
